Introducing Nubytide from Cenna Biosciences: a potential disease-modifying peptide that offers prevention and treatment for Alzheimer’s disease by using a unique mechanism to inhibit the production of Aß.

IND Filing 2024

Proof of Concept 2026-27

About Nubytide

  • Large, growing market - $3.5B+ with 6M US patients

  • Differentiated technology - disease modifying

  • 12 months from funding to first enrolled patient

  • Affordable, easy to administer

Strong IP position

  • 8 issued US patents

  • 10 issued international patents

Nubytide reduces Aß, markers of inflammation and Tau pathology

Nubytide Mission and Vision


Disease Modifying

Better Alternative

Reduces Aß Markers

Mission: Make Nubytide available to every patient in the world suffering from Alzheimer's Disease.

Mission: Nubytide is the proactive therapy to delay or stop the onset of the disease to anyone over the age of 65.

Vision: Alzheimer Disease drugs today are monoclonal antibodies which come with higher costs, are harder to administer and are less safe.

Vision: Why Nubytide? Nubytide is a peptide drug which reduces Aß, markers of inflammation and Tau pathology.

Alzheimer's Disease

Alzheimer's Disease is a growing global epidemic

Global Market

  • Worldwide, at least 55 million people are believed to be living with Alzheimer's disease or other dementias.

  • According to the United Nations, that is more than the population of Colombia.

  • If breakthroughs are not discovered, this number will almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050.

  • One in three seniors dies with Alzheimer's or related dementia.

Bright Focus Foundation – Alzheimer’s Facts and Figures

U.S. Market

Investor Opportunity

Cenna is Poised to Quickly Move Nubytide Through IND to Exit Phases

Cenna Biosciences Team

Cenna has assembled a team of seasoned biopharmaceutical specialists:

Nazneen Dewji, Ph.D.
Founder, President and CEO

Christine Smith, Ph.D.

Marwan Sabbagh, MD
Acting CMO
Professor of Neurology

Archie W. Thurston, Jr.,
Pharmacology Consultant

Grace Furman, Ph.D.
D.A.B.T., Toxicology
President and CEO,

Karlene Cork, Ph.D.
Regulatory Affairs


Cenna Announces Appointment of David H. Crean to Board of Directors

Press Release - December 19th 2023

Cardiff Advisory Managing Partner Has Decades of Experience Guiding Life Sciences and Healthcare Companies Through Pivotal Growth, Won the Alzheimer’s Association of San Diego 2023 Hope Award and Has Been Recognized as One of San Diego’s 500 Most Influential People for the Last Four Years.

The Rise of Strategic Partnerships in Life Sciences: Trends Shaping the Future of Healthcare Innovation

Best Stocks - February 7th 2024

Cenna Biosciences, a biopharmaceutical company in La Jolla, California, appointed David H. Crean to its Board of Directors, effective December 12, 2023. Crean, a Managing Partner at Cardiff Advisory LLC, brought over thirty years of experience in mergers & acquisitions, strategic partnerships, and investments in life sciences and healthcare.

Contact Cenna





505 Coast S Blvd, Suite 407, La Jolla, CA 92037, United States